Status:
ACTIVE_NOT_RECRUITING
Apotransferrin in Atransferrinemia
Lead Sponsor:
Prothya Biosolutions
Conditions:
Congenital Atransferrinemia
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Atransferrinemia is a very rare disorder, which is caused by a deficiency of the protein transferrin. No regular treatment is available for these patients. The objective of this study is to investigat...
Eligibility Criteria
Inclusion
- Established diagnosis of atransferrinemia, defined as serum levels of transferrin below 40 mg/dl
- Informed consent
Exclusion
- Known with allergic reactions against human plasma or plasma products
- Having detectable anti-immunoglobulin A antibodies
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2028
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01797055
Start Date
December 1 2010
End Date
January 1 2028
Last Update
August 3 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinikum Aschaffenburg
Aschaffenburg, Germany
2
AO San Gerardo
Monza, Italy, 20900
3
Vall d'Hebron Hospital
Barcelona, Spain